<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567722</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-083</org_study_id>
    <secondary_id>CDR0000729843</secondary_id>
    <secondary_id>U01CA121947</secondary_id>
    <nct_id>NCT01567722</nct_id>
  </id_info>
  <brief_title>Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies</brief_title>
  <official_title>Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS and Cancer Specimen Resource</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory
      may help doctors learn more about changes that occur in DNA and identify biomarkers related
      to cancer.

      PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To obtain high-quality, clinically annotated tissue from patients with human
           immunodeficiency virus (HIV)-1 malignancy.

        -  To study clinical, genetic, and immunologic parameters that have prognostic significance
           and/or are involved in the initiation and progression of HIV-1 malignancies, including
           complete genomic sequence determination of HIV-associated diffuse large B-cell
           lymphomas, lung cancer, anal cancer, and cervical cancer.

      OUTLINE: This is a multicenter study.

      Patients undergo tumor, lymph node, bone marrow, or skin biopsy, and peripheral blood
      mononuclear cells collection. Samples are submitted to the AIDS Malignancy Consortium (AMC)
      Biorepository and transferred to the AIDS and Cancer Specimen Resource (ACSR). Samples are
      then analyzed by the Genome Science Center of British Columbia (GSC-BC) and the HIV+ Tumor
      Molecular Characterization Project (HTMCP) for full genomic sequencing analysis that may
      include, but are not limited to, array-based gene expression profiling, comparative genome
      hybridization, and single nucleotide polymorphism studies by flow cytometry, cytogenetics,
      and molecular studies. Patients' clinical data, demographics, and treatment given are also
      collected prospectively in order to record treatment outcome and toxicity.

      Patients are followed up at 6 months, 1 year, and 2 years for data-reporting purposes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mutational spectrum of each type of HIV-1 associated malignancy</measure>
    <time_frame>Study entry (prior to chemotherapy initiation)</time_frame>
    <description>Complete genomic sequencing of HIV-1 associated tumor tissue</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh-frozen tissue, Peripheral blood mononuclear cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected males and females age 18 and older with one of the three malignancy types
        studied with available diagnostic biopsy material
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Participants must have a diagnosis of a malignancy or clinical findings suggestive of
             a possible HIV-associated malignancy of one of three types:

               -  Diffuse large B-cell lymphoma

               -  Non-small cell lung malignancy

               -  Cervical cancer

          -  The presence of any of the following conditions will exclude a participant from study
             enrollment:

               -  Absence of sufficient diagnostic tumor-biopsy tissue material to meet the
                  protocol requirements for baseline specimen submission (minimum specimen size of
                  10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the
                  protocol specimen-collection requirements

               -  Participants whose biopsies, for the purpose of this protocol, show a diagnosis
                  of anal intraepithelial neoplasia or cervical intraepithelial neoplasia

               -  Prior treatment for the study malignancy (including neo-adjuvants), since
                  treatment can affect the mutational spectra of tumors

          -  HIV infection based on serologic documentation of HIV infection at any time prior to
             study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA),
             positive western blot, or any other Food and Drug Administration (FDA)-approved
             (licensed) HIV test; alternatively, this documentation may include a record that
             another physician has documented that the patient has HIV based on prior ELISA and
             western blot, or other approved diagnostic tests

        PATIENT CHARACTERISTICS:

          -  Participants must be willing and able to sign an IRB-approved informed consent
             document

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Ratner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University Siteman Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Moores UCSD Cancer Center</last_name>
      <phone>858-822-5354</phone>
      <email>cancercto@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>William Wachsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical AIDS Research and Education (CARE) Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1793</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricela Gonzalez</last_name>
      <phone>310-557-3729</phone>
      <email>mmgonzalez@mednet.ecla.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Mitsuyasu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Ramos, MD</last_name>
      <phone>305-243-6611</phone>
    </contact>
    <investigator>
      <last_name>Juan Carlos Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Rubinstein</last_name>
      <phone>312-864-7277</phone>
    </contact>
    <investigator>
      <last_name>Paul Rubinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Public Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Mederos</last_name>
      <phone>504-568-3235</phone>
      <email>emede1@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Reske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Ratner, MD, PhD</last_name>
      <phone>314-362-8836</phone>
      <email>lratner@im.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Lee Ratner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Albert Einstein Cancer Center at Albe</last_name>
      <phone>718-904-2730</phone>
      <email>aecc@aecom.yu.edu</email>
    </contact>
    <investigator>
      <last_name>Missak Haigentz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariela Noy, MD</last_name>
      <phone>212-639-7423</phone>
      <email>noya@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Ariela Noy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hills</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Richards, MD</last_name>
      <email>kristy_richards@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kristy Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Abramson Cancer Center at Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Beach, MD</last_name>
      <phone>215-829-6088</phone>
      <email>douglas.beach@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Beach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harborview Madison Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kingsley Ndoh</last_name>
      <phone>206-667-3160</phone>
      <email>kndoh@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Corey Casper, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peace Imani, MMED, MPH</last_name>
      <phone>206-667-3160</phone>
      <email>pimani@fhcrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Legg, LPN</last_name>
      <phone>206-744-8748</phone>
      <email>lmlegg@u.washington.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Corey Casper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Ponce</last_name>
      <phone>206-342-6926</phone>
      <email>leila.ponce@vmmc.org</email>
    </contact>
    <investigator>
      <last_name>David Aboulafia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>adult diffuse large cell lymphoma</keyword>
  <keyword>anal cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be submitted to dBGaP</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

